Accuray has received CE Mark approval for the Accuray Helix, a CT-guided helical radiotherapy system designed for high performance and efficiency.
The Wisconsin-based firm intends the system to be accessible in emerging markets where advanced cancer care, including radiotherapy, is often limited to urban areas.
The radiation therapy company said that linear accelerator availability in these regions is significantly below the World Health Organization’s recommended levels.
Accuray Helix is designed to be versatile and easy to use in countries like India, where access to radiotherapy is limited. It supports clinical teams by offering short treatment times and cost-effectiveness, enabling better care for patients in underserved, non-urban communities.
According to Accuray, the CT-guided helical radiotherapy system provides precise, targeted radiation treatments for a range of routine cases commonly encountered by clinical teams.
The radiotherapy system will treat breast, cervical, head and neck, gastrointestinal, lung, and prostate cancers. Its flexibility and versatility are designed to enhance personalisation and patient care, while also increasing clinic productivity.
Additionally, Accuray Helix helps clinics manage the rising demand for cancer care by enabling the treatment of more patients each day.
Accuray president and CEO Suzanne Winter said: “India is a priority due to this disparity as there is a significant deficit in availability of radiation therapy systems compared to the size if its population and incidence of cancer. Our goal with the introduction of Accuray Helix is to close some of these gaps to patient access with our comprehensive solutions.
“The Accuray Helix system combines affordability with automation and tools for enhancing the speed of planning and delivery of radiation.
“We believe it will enable a broader range of capabilities for facilities that may have resources and staffing for only one system, enabling them to offer state-of-the-art cancer care in their communities.”
The latest certification follows Accuray Precision Treatment Planning System (TPS) clearance by the Chinese National Medical Products Administration (NMPA).
In June, Accuray partnered with TrueNorth Medical Physics to improve the capabilities of radiation oncology departments with third-party support.
